[Electrocardiographic interval as a predictor of life-threatening arrhythmias in dilated cardiomyopathy patients]. / Intervalo electrocardiográfico como predictor de arritmias graves en pacientes con miocardiopatía dilatada.

Background: The Tpe interval (Tp-e) in the surface electrocardiogram represents ventricular repolarization, a key phase in the pathogenesis of severe ventricular arrhythmias. However, there are few studies evaluating changes in this electrocardiographic interval as a risk factor for serious arrhythmias in patients with dilated cardiomyopathy. Objective: To determine whether the Tp-e interval prolongation predicts the presence of life-threatening arrhythmias in patients with dilated cardiomyopathy (DCM) with implantable cardioverter-defibrillator (ICD). Material and methods: Analytical, cross-sectional study in patients with DCM with ICDs. The Tp-e interval was measured in the V2 electrocardiographic lead and correlated with the incidence of life-threatening arrhythmias identified by the ICD. Results: 53 patients were recruited, 10 (18.8%) presented life-threatening arrhythmias. Prolongation of Tp-e interval was related to an increase in the incidence of ventricular tachycardia/fibrillation tachycardia (VT/FT) with a mean of 93 ± 20.5 ms (p = 0.003), using ROC curves to determine the thereshold of 90 ms for increased risk of VT/VF with sensitivity of 70% and specificity of 84%, with an area under the curve of 0.798. Conclusion: The prolongation of the ITp-e interval greater than 90 ms in a population with dilated cardiomyopathy predicts the presence of arrhythmic episodes, such as VT and/or VT/FT.

Introducción: el intervalo Tpe (ITp-e) en el electrocardiograma de superficie representa la repolarización ventricular, fase clave en la patogénesis de arritmias ventriculares graves. Sin embargo, existen pocos estudios que evalúen la alteración de este intervalo electrocardiográfico como factor de riesgo de arritmias graves en pacientes con miocardiopatía dilatada. Objetivo: determinar si la prolongación del ITp-e predice la presencia de arritmias potencialmente mortales en pacientes con miocardiopatía dilatada (MCD) portadores de desfibrilador automático implantable (DAI). Material y métodos: estudio, transversal analítico en pacientes con MCD portadores de DAI. Se midió el ITp-e en la derivación electrocardiográfica V2 y se correlacionó con la incidencia de arritmias potencialmente letales identificadas por el DAI. Resultados: se incluyeron 53 pacientes, 10 (18.8%) presentaron arritmias potencialmente mortales. La prolongación del ITp-e se relacionó con aumento de incidencia de taquicardia ventricular/fibrilación ventricular (TV/FV) con media de 93 ± 20.5 ms (p = 0.003), por lo que se determinó mediante curvas ROC el punto de corte de 90 ms para el aumento de riesgo de TV/FV con sensibilidad de 70% y especificidad de 84%, con área bajo la curva de 0.798. Conclusión: la prolongación del intervalo ITp-e > 90 ms en población con miocardiopatía dilatada predice la presencia de episodios arrítmicos como TV o FV.

[LDH-neutrophil-lymphocyte index as a predictor of 28-day mortality in patients with COVID-19]. / Índice DHL-neutrófilos-linfocitos como predictor de mortalidad a 28 días en pacientes con COVID-19.

Background: Coronavirus disease 2019 (COVID-19) represents the greatest health crisis of our times; it was declared by WHO a pandemic in March 2020. The risk of presenting a severe disease is inter-individual, since it varies according to age, comorbidities, and immunological status, in addition to the type of SARS-CoV-2 variant. The neutrophil/lymphocyte ratio (NLR) and lactic dehydrogenase (LDH) are widely used markers to assess the severity and predict the course of the disease in patients with COVID-19, with a direct relationship of higher value-worse prognosis. Objective: To verify if the LDH-neutrophil-lymphocyte index calculated from laboratory tests taken within the first 24 hours of admission is useful as a predictor of 28-day mortality in adult patients diagnosed with COVID-19. Material and methods: Retrospective and analytical cohort study. All consecutive patients over 16 years of any gender, admitted to a tertiary care center from March 2020 to March 2021, who had a diagnosis of COVID-19 with a positive PCR for SARS-CoV-2, were included. Results: Higher levels of the LDHNL index were associated with higher mortality in patients hospitalized for COVID-19 (Q2 vs. Q1: RR 1.52 [1.24-1.87], p < 0.05; Q3 vs. Q1: RR 1.87 [1.55-2.25], p < 0.05; and Q4 vs. Q1: RR 2.74 [2.22-3-39], p < 0.05). Conclusions: The serum LDHNL index taken in the first 24 hours of admission can help to predict early the risk of mortality in hospitalized patients with COVID-19.

Introducción: la enfermedad por coronavirus del 2019 (COVID-19) es la mayor crisis sanitaria de nuestros tiempos; fue declarada pandemia por la OMS en marzo de 2020. El riesgo de presentar enfermedad grave es interindividual y varía según la edad, las comorbilidades, el estado inmunológico y la variante del virus. La relación neutrófilos/linfocitos (RNL) y la deshidrogenasa láctica (DHL) son marcadores muy utilizados para evaluar la gravedad y predecir el curso de la enfermedad en pacientes con COVID-19, con una relación directa de mayor valor-peor pronóstico. Objetivo: comprobar si el índice DHL-neutrófilos-linfocitos calculado con estudios de laboratorio tomados en las primeras 24 horas de ingreso a hospital es útil como predictor de mortalidad a 28 días en pacientes adultos con diagnóstico de COVID-19. Material y métodos: estudio de tipo cohorte retrospectivo y analítico. Se incluyeron consecutivamente todos los pacientes mayores de 16 años de cualquier género, ingresados en un hospital de tercer nivel de marzo de 2020 a marzo de 2021, los cuales presentaron diagnóstico de COVID-19 con PCR positiva de SARS-CoV-2. Resultados: los niveles más altos del índice DHLNL se asociaron con una mayor mortalidad en pacientes hospitalizados por COVID-19 (Q2 frente a Q1: RR 1.52 [1.24-1.87], p < 0.05; Q3 frente a Q1: RR 1.87 [1.55-2.25], p < 0.05; y Q4 frente a Q1: RR 2.74 [2.22-3-39], p < 0.05). Conclusiones: el índice DHLNL en suero tomado en las primeras 24 horas del ingreso puede ayudar a identificar de manera temprana entre los pacientes hospitalizados por COVID-19 a aquellos con mayor riesgo de mortalidad.

[Sodium-chlorine difference as a prognostic predictor in adult patients diagnosed with COVID-19]. / Diferencia sodio-cloro como predictor pronóstico en pacientes adultos con diagnóstico de COVID-19.

Background: Hyperchloremia has been associated with a greater presence of morbidity and mortality, mainly described in critically ill patients, this may be relative and absolute, which could be reflected in the sodium-chloride difference. Objective: The primary objective was to determine whether the sodium-chloride difference <31 mEq/L measured 24-48 hours after admission is a predictor of 28-day mortality in patients with COVID-19, and as secondary objectives to identify whether it is associated with higher requirement for invasive mechanical ventilation, presence of acute kidney injury and longer hospital stay. Material and methods: Retrospective, descriptive and analytical longitudinal cohort study, was done including all consecutive patients older than 16 years of any gender, admitted to the UMAE from March 1, 2020 to March 2021, which present a diagnosis of COVID-19 with RT-PCR test for SARS-CoV-2 positive. Results: A total of 722 patients were included, the difference sodium-chloride < 31 mEq/L is not associated with an increased risk of death at 28 days (p = 1.172, OR: 1.35; 95%CI, 0.87-2.08) or requirement of mechanical ventilation (p = 0.47, OR: 1.19; 95%CI, 0.76-1.86), but is associated with a higher risk of AKI (p < 0.05, OR: 2.04; 95%CI, 1.33- 3.14) and longer hospital stay (p < 0.05). Conclusions: the sodium-chloride difference < 31 mEq/L in the first hours of admission is associated with a higher risk of presenting acute kidney injury during hospital stay in patients with COVID-19, as well as a longer hospital stay.

Introducción: la hipercloremia se ha asociado a mayor presencia de morbimortalidad principalmente en pacientes críticos, pudiendo esta ser relativa y absoluta, la cual se puede reflejar por medio de la diferencia sodio menos cloro. Objetivo: el objetivo primario fue determinar si la diferencia sodio menos cloro < 31 mEq/L medida a las 24-48 horas de ingreso es predictor de mortalidad a 28 días en pacientes con COVID-19, y como objetivos secundarios identificar si se asocia a mayor requerimiento de ventilación mecánica invasiva, presencia de lesión renal aguda y mayor estancia hospitalaria. Material y métodos: estudio de tipo cohorte longitudinal retrospectivo, descriptivo y analítico, se incluyeron todos los pacientes blanco de manera consecutiva mayores de 16 años de cualquier género, ingresados en la UMAE No. 1 del Bajío de marzo del 2020 a marzo 2021, los cuales presentan diagnóstico de COVID-19 con PCR para el ARN de Sars-Cov2 positiva. Resultados: se incluyeron en total 722 pacientes, la diferencia sodio menos cloro < 31 mEq/L no se asocia a incremento del riesgo de muerte a 28 días (p = 1.172, OR: 1.35; IC95%: 0.87-2.08) ni requerimiento de ventilación mecánica (p = 0.47, OR: 1.19; IC95%: 0.76-1.86), pero sí a mayor riesgo de presentación de LRA (p < 0.05, OR: 2.04; IC95%: 1.33- 3.14) y mayor estancia hospitalaria (p < 0.05). Conclusiones: la diferencia sodio menos cloro < 31 mEq/L en las primeras horas del ingreso se asocia a mayor riesgo de presentar lesión renal aguda durante la estancia hospitalaria en pacientes con la COVID-19, así como mayor tiempo de estancia hospitalaria.

Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial.

HIV-seropositive patients show high incidence of coronary heart disease and oxidative stress has been described as relevant key in atherosclerosis development. The aim of this study was to assess the effect of omega 3 fatty acids on different markers of oxidative stress in HIV-seropositive patients. We performed a randomized parallel controlled clinical trial in The Instituto Mexicano del Seguro Social, a public health hospital. 70 HIV-seropositive patients aged 20 to 55 on clinical score A1, A2, B1 or B2 receiving highly active antiretroviral therapy (HAART) were studied. They were randomly assigned to receive omega 3 fatty acids 2.4 g (Zonelabs, Marblehead MA) or placebo for 6 months. At baseline and at the end of the study, anthropometric measurements, lipid profile, glucose and stress oxidative levels [nitric oxide catabolites, lipoperoxides (malondialdehyde plus 4-hydroxialkenals), and glutathione] were evaluated. Principal HAART therapy was EFV/TDF/FTC (55%) and AZT/3TC/EFV (15%) without difference between groups. Treatment with omega 3 fatty acids as compared with placebo decreased triglycerides (-0.32 vs. 0.54 mmol/L; p = 0.04), but oxidative stress markers were not different between groups.